Altoida develops digital health solutions for cognitive assessment and monitoring.

Altoida

Altoida is a pioneer in developing digital biomarkers of neurological conditions, including Alzheimer’s Disease, using augmented reality and machine learning. Our technology platform is designed to enable an objective evaluation of an individual’s cognitive health and function, which may potentially allow for faster and more sensitive monitoring of disease progression and treatment response. Altoida is a privately-held, venture-backed, commercial stage company and our proprietary evidence-based platform is founded on more than 20 years of scientific research and published in multiple peer-reviewed papers including Nature Digital Medicine.

FYRFLY Venture Partners

VI Partners

Alpana Ventures

Hikma Ventures

Polytech Ventures

M Ventures

Grey Sky Venture Partners

btov Partners

Whitecap Venture Partners

HonorHealth

Eisai Innovation

Alzheimer's Drug Discovery Foundation

Altoida, Inc.

This September, we join the global community in recognizing World Alzheimer's Month—a time to raise awareness and support those affected by Alzheimer’s disease. Currently, over 55 million people worldwide live with Alzheimer's disease and other dementias, a number expected to reach 78 million by 2030, making it one of the most urgent healthcare challenges facing our world today. 

Advances in early diagnosis and innovative disease modifying treatments are paving the way for a brighter future. At Altoida, we are dedicated to advancing research and innovation to improve early diagnosis to enable treatment options for Alzheimer's and other neurodegenerative diseases. Our NeuroMarker platform leverages machine learning and augmented reality and is designed for early detection of Mild Cognitive Impairment (MCI). By identifying the condition sooner, we hope to empower healthcare providers and patients so treatments can begin sooner, when it can be most effective.

Join us in spreading awareness this World Alzheimer's Month and help us in our mission to improve cognitive health and quality of life for millions around the world. By raising awareness, we can encourage more people to seek information and support, promote further research and address the growing need for access to diagnosis and treatment. This makes World Alzheimer’s Month more important than ever.

#TimeToActOnDementia #TimeToActOnAlzheimers #WorldAlzMonth #AlzheimersAwareness #DigitalHealth #Neurotech #Altoida  #MachineLearning

New research highlights the complexities in identifying risk and protective factors for Alzheimer's disease. A recent Nature Digital Medicine study emphasizes the influence of genetic and environmental elements, the challenge of pinpointing specific biomarkers, and the need for personalized approaches in Alzheimer's prevention and treatment.

We remain dedicated to advancing the research of neurological disorders through cutting-edge technology. By utilizing machine learning and augmented reality, these innovations offer personalized insights into cognitive and functional abilities. This progress enables real-time endpoints for the early detection of cognitive deficits.

Read the full study here: https://lnkd.in/gKYXidtk

#Alzheimers #DigitalBiomarkers #Altoida #DigitalHealth #MedTech #HealthTech #HealthcareInnovation #MachineLearning #AugmentedReality

The recent FDA approval of Eli Lilly and Company’s donanemab marks another significant milestone in Alzheimer’s disease research and treatment. This breakthrough promises not only a new therapeutic option for patients but also ignites hope for future advancements in combating Alzheimer’s disease. It underscores the importance of ongoing innovation in Alzheimer’s research, paving the way for improved patient outcomes and potentially transforming the landscape of neurodegenerative diseases.

At Altoida, we’re committed to transforming Alzheimer’s care with our innovative Altoida Digital Biomarker Diagnostic Platform. Our diagnostic platform, powered by machine-learning and augmented-reality is designed for early diagnoses, allowing patients to begin treatment sooner, when it can still be most effective.

As we celebrate this milestone in Alzheimer’s treatment, we remain dedicated to advancing innovative solutions that help patients maintain their independence and quality of life for as long as possible.

Learn more about the FDA approval here: https://lnkd.in/gYrhers2
=It%20has%20received%20traditional%20approval,beta%2Damyloid%20in%20the%20brain

#Alzheimers #DigitalBiomarkers #Altoida #DigitalHealth #MedTech #DigitalHealth #HealthTech #HealthcareInnovation #MachineLearning #AugmentedReality

Thanks Philadelphia & Alzheimer's Association® for an insightful and action-packed week at #AAIC2024! It was inspiring to connect with so many passionate professionals dedicated to Alzheimer’s disease research, advancing clinical trials and improving patient outcomes. We're excited to continue contributing to the fight against Alzheimer's by enabling earlier detection!

Missed us at the event? Learn more or schedule a meeting with us here: https://lnkd.in/gkrZRxtH

#DigitalBiomarkers #DigitalHealth #HealthTech #Dementia #Alzheimers #CognitiveHealth #Altoida #EndALZ

Marc Jones Emmanuel Streel M. Florencia Iulita John Dwyer Vijaya B. Kolachalama

The Altoida team will be attending the Alzheimer's Association® International Conference next week in Philadelphia. We will showcase how Altoida’s digital biomarker platform offers the potential to advance clinical trials by capturing clinically meaningful cognitive and functional changes faster than traditional neuropsych evaluations.

To learn more or meet, schedule a meeting here: https://lnkd.in/gkrZRxtH

#AAIC2024 #DementiaResearch #AlzheimersResearch #Alzheimers #DigitalBiomarkers #Altoida #DigitalHealth #MedTech #DigitalHealth #HealthTech #HealthcareInnovation #AugmentedReality #MachineLearning

The Alzheimer's Association® and National Institute Of Aging have released new criteria that signal an era of innovation in understanding, diagnosing, and managing Alzheimer's disease. The new criteria focus on biomarkers in diagnosing and staging Alzheimer's, pushing for diagnoses based on Core 1 and Core 2 biomarkers, rather than just clinical symptoms. Core 1 biomarkers include early changing indicators like amyloid positron emission tomography (PET), cerebrospinal fluid (CSF) biomarkers, and plasma biomarkers, while Core 2 biomarkers include later-changing indicators such as biofluid and tau PET.

The criteria propose a multi-stage progression model based on biomarkers to help assess the severity of Alzheimer’s. The use of biomarkers is recommended for evaluating symptomatic individuals and determining their eligibility for treatments. 

As we at Altoida continue to advance our Digital Biomarker Platform for neurodegenerative disorders, we are excited to see this recognition in the potential of digital cognitive testing which offers the potential to reliably detect subtle cognitive changes through repeated testing, opening new possibilities for early and accurate diagnosis.

Review the updated criteria here: https://lnkd.in/g3PT8HBf

#CognitiveHealth #DigitalCognitiveTesting #HealthInnovation #Alzheimers #DigitalBiomarkers #Altoida #DigitalHealth #MedTech #DigitalHealth
#HealthTech #HealthcareInnovation

Our entire team at Altoida, Inc. congratulates Eli Lilly and Company 🎉 on the FDA approval of their Alzheimer's treatment, donanemab. This is yet another monumental milestone for patients, caregivers, and healthcare providers.  Well done! 👏  #FDAApproval #Alzheimers #Innovation 

https://lnkd.in/e-TC6rMn

At Altoida, we continue to pioneer the development of digital biomarkers to identify neurological disease, including Alzheimer’s, earlier. By using augmented reality and machine learning, the Altoida platform is designed to offer insights into patients' cognitive and functional abilities, providing real-time endpoints for early indications of cognitive deficits.

Unlike traditional neuropsychological assessments that can be time-consuming and subjective, the Altoida platform is a 10-minute assessment designed to enable the accurate measurement and monitoring of cognitive function using just a tablet.

Learn more about the Altoida Digital Biomarker Platform and how it has the potential to help clinicians and researchers better understand brain network function and the impacts of new and emerging disease modifying treatments: https://lnkd.in/gBwXUfi8

#Alzheimers #DigitalBiomarkers #Altoida #DigitalHealth #MedTech #DigitalHealth #HealthTech #HealthcareInnovation #AugmentedReality #MachineLearning

This month is Brain and Alzheimer's Awareness Month, and it serves as a timely reminder to prioritize our brain health. 🧠 Studies show, the actions we take today can lead to a healthier mind tomorrow. Incorporate healthy habits like learning new skills, regular physical activity, quitting smoking, getting good quality sleep, and eating healthier. Small steps can make a big difference in maintaining a healthy brain and slowing or preventing cognitive decline.

Altoida’s mission is to enable early diagnoses of neurodegenerative disorders, giving you, your loved ones and healthcare practitioners an effective resource to enable a better future.

Take this month to learn more about your brain health and the positive impact small lifestyle changes can make. Keep learning, stay curious and always remember - your brain matters! 💡

Read more about healthy changes you can make for your brain: https://lnkd.in/eANEpdHh
Alzheimer's Association®

#ENDALZ #Alzheimers #DigitalBiomarkers #Altoida #DigitalHealth #MedTech #DigitalHealth #HealthTech #HealthcareInnovation

This week, Eli Lilly and Company’s donanemab received unanimous support from an FDA advisory committee in favor of its efficacy and positive benefit-risk profile for patients with mild cognitive impairment and mild dementia. The committee praised donanemab as an innovative therapy and as industry stakeholders, we applaud this development, signifying a positive step towards an effective treatment for Alzheimer’s.

We remain committed to collaborating with industry leaders to achieve a common goal - to change the lives of millions suffering from Alzheimer's by striving to deliver early diagnoses to access effective treatments.

To learn about donanemab's FDA approval, read more here: https://lnkd.in/gnVypxSb

#Alzheimers #DigitalBiomarkers #Altoida #DigitalHealth #MedTech #DigitalHealth #HealthTech #HealthcareInnovation

Metric
Company Name	Altoida
Symbol
MSH ID	COM:ALTOIDA
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Digital Health Technology
Country	US
Stage
Employee Count	11
Website	altoida.com
LinkedIn	altoida
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

ALTO

COM:ALTOIDA

Altoida

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue